分析师升级后，MannKind（纳斯达克股票代码：MNKD）创下52周新高_新浪财经

MannKind Co. (NASDAQ:MNKD – Get Rating) hit a new 52-week high during mid-day trading on Monday after HC Wainwright raised their price target on the stock from $6.00 to $7.00. The company traded as high as $5.73 and last traded at $5.70, with a volume of 1180271 shares traded. The stock had previously closed at $5.41.

A number of other brokerages have also recently issued reports on MNKD. StockNews.com raised shares of MannKind from a "sell" rating to a "hold" rating in a research note on Friday, November 11th. SVB Leerink increased their price objective on shares of MannKind from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 9th.

Get

MannKind

alerts:

Hedge Funds Weigh In On MannKind

Several institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. grew its stake in MannKind by 2.0% during the fourth quarter. Alliancebernstein L.P. now owns 254,500 shares of the biopharmaceutical company's stock valued at $1,341,000 after acquiring an additional 5,100 shares in the last quarter. State of Wisconsin Investment Board lifted its position in MannKind by 0.9% during the fourth quarter. State of Wisconsin Investment Board now owns 245,286 shares of the biopharmaceutical company's stock valued at $1,293,000 after purchasing an additional 2,250 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its position in MannKind by 3.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,862,900 shares of the biopharmaceutical company's stock valued at $15,087,000 after purchasing an additional 83,668 shares during the last quarter. Squarepoint Ops LLC lifted its position in MannKind by 72.5% during the fourth quarter. Squarepoint Ops LLC now owns 152,375 shares of the biopharmaceutical company's stock valued at $803,000 after purchasing an additional 64,046 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in MannKind by 4.4% during the fourth quarter. Legal & General Group Plc now owns 88,134 shares of the biopharmaceutical company's stock valued at $464,000 after purchasing an additional 3,720 shares during the last quarter. 49.16% of the stock is owned by hedge funds and other institutional investors.

MannKind Price Performance

The company's 50-day simple moving average is $5.14 and its 200 day simple moving average is $4.29. The firm has a market cap of $1.42 billion, a P/E ratio of -15.82 and a beta of 1.65.

MannKind (NASDAQ:MNKD – Get Rating) last released its quarterly earnings data on Thursday, February 23rd. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The business had revenue of $36.06 million for the quarter, compared to analyst estimates of $35.51 million. The firm's revenue was up 188.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) EPS. Analysts anticipate that MannKind Co. will post -0.13 EPS for the current fiscal year.

MannKind Company Profile

(Get Rating)

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.